DRREDDYBSEDr Reddys Laboratories Ltd· Pharmaceuticals & BiotechnologyHighNegative
Announced Thu, 9 Jul, 2026 · 09:16 IST

Semaglutide batches out of spec, supplies delayed

Monthly Volume DeclinedBusiness Updates View source PDFExplain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-5.9%Reaction day
₹1351.10
prior close
₹1335.90
announcement price
In-mkt
timing
Nifty 100market+0.4%-6.3% vs market
Pharmaceuticals peers, median of 166sector+0.9%-6.9% vs sector

On the reaction day the stock moved 6.3 pts less than Nifty 100 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.1
10m
-1.6
15m
-0.2
30m
+0.9
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-5.9+0.4-6.3+0.9-6.9
Next day
-7.7+1.5-9.2+1.4-9.1
2d
-8.5+1.4-9.9+1.8-10.3
3d
-7.8+0.8-8.6+1.4-9.2
4d
-9.0+1.0-10.0+1.6-10.5
5d
-9.3+0.9-10.2+1.6-10.9
1w
-9.6+1.6-11.2+1.2-10.8
15d
-15.3+2.0-17.3-0.5-14.8
1m
-14.2+3.4-17.6+0.8-15.0
2m
-15.3-1.0-14.2+2.7-18.0
3m
-11.4-5.4-6.0-0.8-10.6
UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr Reddys found certain batches of semaglutide out of specification due to an issue with the active pharmaceutical ingredient. Commercial supplies of the product will be delayed until the root cause is identified and fixed. The company says there is no impact on patient safety or on existing global regulatory filings. Management has scheduled a conference call today at 16:30 IST to discuss the matter and answer questions.

Likely market impact

Near-term revenue from semaglutide sales may take a hit due to supply delays. Investors should watch the management call for clarity on duration and financial impact.